ライフサイエンスコーパス: typical antipsychotic

1 cal antipsychotic, but not by haloperidol, a typical antipsychotic.

2 iological trait unaffected by treatment with typical antipsychotics.

3 ctioning in schizophrenic subjects receiving typical antipsychotics.

4 e seven studies that compared clozapine to a typical antipsychotic, a meta-analysis was performed to

5 os were calculated for users of atypical and typical antipsychotics adjusting for known cataractogeni

6 rt-term benefits with the continued use of a typical antipsychotic after achieving remission from an

7 rmine the benefits of the continued use of a typical antipsychotic agent following remission from an

8 on of D2 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D2

9 Moreover, we identified that the typical antipsychotic agent pimozide is a SCOT inhibitor

10 ipsychotic drugs, by definition, differ from typical antipsychotic agents in producing significantly

11 eficial therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous ant

12 Typical antipsychotic and atypical antipsychotic subject

13 drug washout after chronic treatment with a typical antipsychotic and before prospective treatment w

14 Haloperidol, a typical antipsychotic and D2R blocker, reduced AMPH hype

15 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their

16 again in comparison with patients receiving typical antipsychotics and untreated control subjects.

17 iving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control su

18 ms during the first week of treatment with a typical antipsychotic are unlikely to respond to a 4-wee

19 oints, in comparison with patients receiving typical antipsychotics as well as untreated healthy cont

20 es when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric

21 One compound, the typical antipsychotic azaperone, improved the motility o

22 y required failure in trials of at least two typical antipsychotics before initiation of an atypical

23 Typical antipsychotics can cause disabling side effects.

24 death in elderly patients with dementia, the typical antipsychotics carry an even higher risk of deat

25 Haloperidol is a typical antipsychotic drug (APD) associated with an incr

26 psychoses often involves treatment with the typical antipsychotic drug and dopamine D2 receptor anta

27 and 3.1% (95% CI, 2.7%-3.5%) in infants with typical antipsychotic drug exposure in utero.

28 , significantly potentiated the ability of a typical antipsychotic drug haloperidol, a D2 receptor an

29 Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine

30 actions of UNC9975 and transformed it into a typical antipsychotic drug with a high propensity to ind

31 ellular D2LR signaling mediated effects of a typical antipsychotic drug, haloperidol, in inducing cat

32 idal side effects associated with the use of typical antipsychotic drugs (e.g., haloperidol).

33 e, 26-31 years), and 6371 mothers exposed to typical antipsychotic drugs (mean age range, 27-32 years

34 Atypical and typical antipsychotic drugs alter GSK-3 activity, as do

35 e, five subjects who were being treated with typical antipsychotic drugs and five subjects who were b

36 and other medications, they do suggest that typical antipsychotic drugs and lithium have contrasting

37 Typical antipsychotic drugs are widely thought to allevi

38 Typical antipsychotic drugs do not improve this deficit

39 aired visual contrast detection, those given typical antipsychotic drugs exhibited higher visual cont

40 Users of typical antipsychotic drugs have an increased risk of se

41 ntipsychotic drugs as compared with users of typical antipsychotic drugs was 1.14 (95% CI, 0.93 to 1.

42 Typical antipsychotic drugs, such as haloperidol and chl

43 Among users of typical antipsychotic drugs, the incidence-rate ratios i

44 s) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be m

45 d effect sizes for baseline treatment with a typical antipsychotic (>6 months treatment), drug washou

46 Chronic administration of the typical antipsychotic haloperidol (1 mg/kg) and the atyp

47 dy neurons and by acute oral delivery of the typical antipsychotic haloperidol and the atypical cloza

48 the atypical antipsychotic clozapine and the typical antipsychotic haloperidol could modulate the eff

49 ifically, antagonism of D2R signaling by the typical antipsychotic haloperidol induces parkinsonism i

50 c, as it was not observed with exposure to a typical antipsychotic, haloperidol or an atypical antips

51 ted that clozapine exhibits superiority over typical antipsychotics in terms of both efficacy (as mea

52 than G-protein-dependent signaling, whereas typical antipsychotics inhibit both pathways with simila

53 In contrast, the patients receiving typical antipsychotic medications had dramatically lower

54 ransdermal patch and with either atypical or typical antipsychotic medications.

55 ic episode treated with the combination of a typical antipsychotic (perphenazine) and a mood stabiliz

56 xia) and that several psychotic symptoms are typical antipsychotic resistant and atypical antipsychot

57 olinergic interneurons and the mechanisms of typical antipsychotic side effects.

58 The effect size for clozapine, compared with typical antipsychotics, suggests that the drug-washout l

59 tected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparin

60 sychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated cont